The emerging role of reactive oxygen species in cancer therapy

European Journal of Cancer

Volumn 40, Issue 13, 2004, Pages 1934-1940

  Renschler, Markus F ^a,b  

^a PHARMACYCLICS INC   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Apoptosis; Buthionine sulfoximine; Hydrogen peroxide; Motexafin gadolinium; Procarbazine; Reactive oxygen species; ROS

Indexed keywords

BUTHIONINE SULFOXIMINE; GADOLINIUM TEXAPHYRIN; PROCARBAZINE; REACTIVE OXYGEN METABOLITE;

CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DNA DEGRADATION; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 4143066896     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.02.031     Document Type: Article

References (57)

1. Berneis K., Kofler M., Bollag W., Kaiser A., Langeman A. The degradation of deoxyribonucleic acid by new tumour inhibiting compounds: the intermediate formation of hydrogen peroxide. Experientia. 19:1963;132-133
2. Berneis K., Bollag W., Kofler M., Luthy H. The enhancement of the after effect of ionizing radiation by a cytotoxic methylhydrazine derivative. Eur. J. Cancer. 2(1):1966;43-49
3. Martz G., D'Alessandri A., Keel H.J., Bollag W. Preliminary clinical results with a new antitumor agent RO 4-6467 (NSC 77213). Cancer Chemother. Rep. 33:1963;5-14
4. Mathe G., Schweisguth O., Schneider M., et al. Methyl-hydrazine in treatment of Hodgkin's disease and various forms of hematosarcoma and leukemia. Lancet. 12:1963;1077-1080
5. Zeller P., Gutmann H., Hegedus B., et al. Methylhydrazine derivatives, a new class of cytotoxic agents. Experientia. 19:1963;129
6. Bollag W., Grunberg E. Tumour inhibitory effects of a new class of cytotoxic agents: methylhydrazine derivatives. Experientia. 19:1963;130-131
7. Miller E. Development of procarbazine. Carter S.K. Proceedings of the Chemotherapy Conference on Procarbazine (Mutulane: NSC-77213): Development and Application. 1970;3-7 Cancer Therapy Evaluation Branch, National Cancer Institute, Bethesda, MA
8. Rutishauser A., Bollag W. Cytological investigations with a new class of cytotoxic agents: methylhydrazine derivatives. Experientia. 19:1963;131-132
9. Berneis K., Kofler M., Bollag W. The influence of chelating agents on the prooxidative effect of a hydrogen peroxide producing methylhydrazine compound. Experientia. 20(2):1964;73-74
10. Kreis W. Mechanism of action of procarbazine. Carter S.K. Proceedings of the Chemotherapy Conference on Procarbazine (Matulane: NSC-77213): Development and Application. 1970;35-44 Cancer Therapy Evaluation Branch National Cancer Institute, Bethesda, MA
11. Connor A.M., Sigdestad C.P. Combined effect of procarbazine and ionizing radiation on mouse jejunal crypts. Chemotherapy. 24(6):1978;368-373
12. Reed D. Metabolism and mechanism of action of procarbazine. Carter S.K. Proceedings of the Chemotherapy Conference on Procarbazine (Matulane: NSC-77213): Development and Application. 1970;45-56 Cancer Therapy Evaluation Branch, National Cancer Institute, Bethesda, MA
13. Sandison A.G., Falskon G., Fichardt T., Savage D.J. A statistical evaluation of the treatment of 215 patients with advanced bronchial cancer managed by telecobalt therapy alone, and in combination with various cancer chemotherapeutic agents. South African Journal of Radiology. 5(2):1967;21-28
14. Falkson G., Falkson H.C., Fichardt T. Radiosensitization by procarbazine in the treatment of malignant mesothelioma. Moroson H.L., Quintiliani M. Radiation Protection and Sensitization. 1970;499 Taylor and Francis, London
15. Landgren R.C., Hussey D.H., Samuels M.L., Leary W.V. A randomized study comparing irradiation alone to irradiation plus procarbazine in inoperable bronchogenic carcinoma. Radiology. 108(2):1973;403-406
16. Palmer R.L., Kroening P.M. Comparison of low dose radiation therapy alone or combined with procarbazine (NSC-77213) for unresectable epidermoid carcinoma of the lung, state T3, N1, N2, or M1. Cancer. 42(2):1978;424-428
17. Roberts P.B. Radiosensitization of E. coli B/r by the cytotoxic agent procarbazine: a hypoxic cell sensitizer preferentially toxic to aerobic cells and easily oxidized. Br. J. Cancer. 39(6):1979;755-760
18. Adams G.E., Cooke M.S. Electron-affinic sensitization. I. A structural basis for chemical radiosensitizers in bacteria. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 15(5):1969;457-471
19. Wasserman T. Chemical modifiers of radiation. Perez C.A., Brady L.W. Principles and practice of radiation oncology. 1998;685-704 Lippincott-Raven Publishers, Philadelphia
20. Nelson D.F., Schoenfeld D., Weinstein A.S., et al. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study. Int. J. Radiat. Oncol. Biol. Phys. 9(8):1983;1143-1151
21. Fazekas J., Pajak T.F., Wasserman T., et al. Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 13(8):1987;1155-1160
22. Simpson J.R., Bauer M., Wasserman T.H., et al. Large fraction irradiation with or without misonidazole in advanced non-oat cell carcinoma of the lung: a phase III randomized trial of the RTOG. Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 13(6):1987;861-867
23. Simpson J.R., Bauer M., Perez C.A., et al. Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer: report of an RTOG prospective randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 16(6):1989;1483-1491
24. Komarnicky L.T., Phillips T.L., Martz K., et al. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int. J. Radiat. Oncol. Biol. Phys. 20(1):1991;53-58
25. Brunner K.W., Young C.W. A methylhydrazine derivative in Hodgkin's disease and other malignant neoplasms. Therapeutic and toxic effects studied in 51 patients. Ann. Int. Med. 63:1965;69-86
26. DeVita V.T. Jr., Simon R.M., Hubbard S.M., et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann. Int. Med. 92(5):1980;587-595
27. DeVita V.T. Jr., Serpick A.A., Carbone P.P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann. Int. Med. 73(6):1970;881-895
28. Klimo P., Conners J.M. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J. Clin. Oncol. 3(9):1985;1174-1182
29. Duggan D.B., Petroni G.R., Johnson J.L., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J. Clin. Oncol. 21(4):2003;607-614
30. Diehl V., Franklin J., Pfreundschuh M., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl. J. Med. 348(24):2003;2386-2395
31. Vose J., Armitage J., Weisenburger D., et al. ChlVPP - an effective and well-tolerated alternative to MOPP therapy for Hodgkin's disease. Am. J. Clin. Oncol. 11(4):1988;423-426
32. Bakemeier R.F., Anderson J.R., Costello W., et al. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. Ann. Int. Med. 101(4):1984;447-456
33. Oliverio V. Pharmacologic disposition of procarbazine. Carter S.K. Proceedings of the Chemotherapy Conference on Procarbazine (Matulane: NSC-77213): Development and Application. 1970;19-28 Cancer Therapy Evaluation Branch, National Cancer Institute, Bethesda, MD
34. Gutin P.H., Wilson C.B., Kumar A.R., et al. Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer. 35(5):1975;1398-1404
35. Bouffet E., Jouvet A., Thiesse P., Sindou M. Chemotherapy for aggressive or anaplastic high grade oligodendrogliomas and oligoastrocytomas: better than a salvage treatment. Br. J. Neurosurg. 12(3):1998;217-222
36. Lyss A.P. Enzymes and random synthetics. Perry M.C. The chemotherapy source book. 1992;398-412 Williams& Wilkins, Baltimore
37. Costantini P., Jacotot E., Decaudin D., Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J. Natl. Cancer Inst. 92(13):2000;1042-1053
38. Hasinoff B.B., Davey J.P. Adriamycin and its iron (III) and copper (II) complexes. Glutathione-induced dissociation; cytochrome c oxidase inactivation and protection; binding to cardiolipin. Biochem. Pharmacol. 37(19):1988;3663- 3669
39. Bellosillo B., Villamor N., Lopez-Guillermo A., et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 98(9):2001;2771-2777
40. Rudin C.M., Yang Z., Schumaker L.M., et al. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res. 63(2):2003;312-318
41. Skapek S.X., Colvin O.M., Griffith O.W., et al. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice. Cancer Res. 48(10):1988;2764-2767
42. Bailey H.H., Mulcahy R.T., Tutsch K.D., et al. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J. Clin. Oncol. 12(1):1994;194-205
43. Bailey H.H., Ripple G., Tutsch K.D., et al. Phase I study of continuous-infusion L-S, R-buthionine sulfoximine with intravenous melphalan. J. Natl. Cancer Inst. 89(23):1997;1789-1796
44. O'Dwyer P.J., Hamilton T.C., LaCreta F.P., et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J. Clin. Oncol. 14(1):1996;249-256
45. Magda D., Lepp C., Gerasimchuk N., et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int. J. Radiat. Oncol. Biol. Phys. 51(4):2001;1025-1036
46. Xu S., Zakian K., Thaler H., et al. Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int. J. Radiat. Oncol. Biol. Phys. 49(5):2001;1381-1390
47. Evens AM, Gartenhaus RB, Prachand S, Nelson JA, Miller RA, Gordon LI. Motexafin gadolinium (MGd) is cytotoxic to steroid and chemotherapy-resistant myeloma cell lines: striking enhancement of apoptosis by redox regulation. In: Seventh International Congress on Hematologic Malignancies, 2003, Ref Type: Abstract
48. Miller R.A., Woodburn K.W., Fan Q., et al. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin. Cancer Res. 7(10):2001;3215-3221
49. Young S.W., Qing F., Harriman A., et al. Gadolinium (III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc. Natl. Acad. Sci. USA. 93(13):1996;6610-6615
50. Miller R.A., Woodburn K., Fan Q., et al. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int. J. Radiat. Oncol. Biol. Phys. 45(4):1999;981-989
51. Carde P., Timmerman R., Mehta M.P., et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J. Clin. Oncol. 19(7):2001;2074-2083
52. Mehta M.P., Shapiro W.R., Glantz M.J., et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J. Clin. Oncol. 20(16):2002;3445-3453
53. Rosenthal D.I., Nurenberg P., Becerra C.R., et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin. Cancer Res. 5(4):1999;739-745
54. Viala J., Vanel D., Meingan P., et al. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. Radiology. 212(3):1999;755-759
55. Carde P., Timmerman R., Mehta M.P., et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J. Clin. Oncol. 19(7):2001;2074-2083
56. Mehta M.P., Rodrigus P., Terhaard C.H., et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol. 21(13):2003;2529-2536
57. Meyers C.A., Smith J.A., Bezjak A., et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J. Clin. Oncol. 22(1):2004;157-165